Key Takeaways from Asembia 2026: Rethinking Patient Access
Being at Asembia 2026, what stood out was not just what was presented but what was openly acknowledged. In conversations across the floor, there was a noticeable shift from showcasing progress to questioning what is still not working.
A few days after the event wrap-up, that perspective feels even more relevant. The industry has made meaningful strides, yet it is also entering a phase of recalibration.
Patient access, once seen as an operational necessity, is now central to outcomes, experience, and speed to therapy. And despite the progress, the gaps are hard to ignore.Â
Fragmentation in Focus at Asembia 2026
One of the clearest takeaways from Asembia 2026 was that progress in patient access is real and visible. Conversations across sessions reflected how far the industry has come with digital tools, hub platforms, and more structured data ecosystems.
And yet, in many of the discussions we were part of, a familiar challenge kept resurfacing. The journey is still not as connected as it needs to be.
What has changed is the nature of fragmentation. It is no longer about the absence of systems, but about how those systems interact. Teams spoke about navigating multiple platforms to complete a single workflow, about approvals that move forward but not always with clarity, and about visibility that exists in parts rather than across the full journey.
There was also a noticeable shift in how this challenge is being approached. Instead of treating fragmentation as an operational inconvenience, there is growing recognition of its impact on time to therapy and overall patient experience. More importantly, there is a stronger willingness across stakeholders to address it collectively. It is a sign that while the problem has evolved, so has the intent to solve it.
Specialty Therapies Are Redefining the Access Journey
A consistent theme across this global conference was how specialty pharma is reshaping the way patient access is structured. With the rise of rare disease treatments and high-cost therapies, the journey is no longer straightforward.
In several conversations, there was a clear acknowledgment that access today depends on tighter coordination between patient support programs, payers, and evolving regulatory frameworks. Each layer adds necessary value, but also introduces complexity that needs to be actively managed.
What stood out was a shared understanding that this complexity is not temporary. It is becoming the new baseline, and it calls for access ecosystems that are just as adaptive and well-orchestrated.
GenAI Is Now Being Measured by Impact
GenAI was no longer a future-facing concept at Asembia this year. It came up in practical terms across conversations around hub operations and patient support programs.
Teams spoke about its role in speeding up prior authorizations, improving eligibility checks, and enabling more responsive decisioning. The focus was not on experimentation, but on outcomes that can be measured and sustained.
What felt different this time was the shift in expectation. The question is no longer whether GenAI should be part of the ecosystem, but how effectively it can be implemented to deliver consistent value.
Connected Data at Asembia 2026: Foundation, Not the Finish Line
At Asembia 2026, interoperability was not discussed as a technical ambition but as a practical necessity. Conversations consistently pointed to the importance of seamless data flow across EHRs, PBMs, and hub platforms.
What we observed was how quickly the narrative has shifted. It is no longer about integrating systems over time, but about building ecosystems that are connected from the start. Because without that continuity, even the most advanced solutions struggle to deliver meaningful impact.
There is a growing understanding that true progress in patient access depends on how well systems communicate, not just how well they perform individually.
A Broader View of What Success Looks Like
Across many of the discussions, there was a clear shift in how success in patient access is being defined. Efficiency continues to matter, but it is no longer the only lens.
More attention is now being given to how patients actually experience the journey. Conversations repeatedly touched on the need for clearer communication, more personalized support, and reducing the uncertainty that patients often face along the way.
It is a shift from simply completing processes to creating a journey that feels understandable and supportive. And increasingly, that is what progress in patient access is being measured against.
What the Right HealthTech Partnership Looks Like Today
A more practical thread across conversations was the role of technology partners in making all of this work in the real world. As GenAI continues to reshape hub and patient support programs, expectations from partners have become far more defined.
There was strong alignment on a few non-negotiables:
- Proven experience applying GenAI in real healthcare settings
- Seamless integration across claims, payer, and prescription data
- Scalable and secure cloud infrastructure
- Interoperability with existing ecosystems
- Real-time decisioning and automation
- Measurable outcomes with faster implementation cycles
- Patient-centric personalization
- Continuous innovation aligned with regulatory shifts
What stood out was not just the list itself, but the clarity behind it. Technology alone is not enough. Execution, adaptability, and domain depth are what ultimately define impact.
Where Do We Go From Here
Stepping back from the conversations at Asembia 2026, a clear direction begins to take shape. The future of patient access will not be defined by isolated innovation or incremental fixes.
What is emerging instead is a more connected approach. One that brings together ecosystems that communicate seamlessly, automation that is intelligent and purposeful, and a deeper understanding of the patient journey as a whole.
For us at Neutrino, these conversations reinforced something we have long believed. Real progress in patient access comes from pairing technology with context and approaching innovation with clear intent.
The Conversation Continues
What stayed with us after Asembia 2026 was not just the ideas but the questions that are still unfolding. Because patient access is not a problem to be solved once. It is a journey that keeps evolving with every conversation.
If these perspectives resonate, we would value the opportunity to continue this dialogue and explore what meaningful progress can look like together.
Connect with our team to take the conversation forward. Until next time.